Xenon Pharmaceuticals Inc. to Post Q4 2017 Earnings of $0.22 Per Share, Jefferies Group Forecasts (XENE)
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Equities researchers at Jefferies Group decreased their Q4 2017 EPS estimates for shares of Xenon Pharmaceuticals in a research report issued to clients and investors on Wednesday. Jefferies Group analyst M. Raycroft now anticipates that the biopharmaceutical company will earn $0.22 per share for the quarter, down from their prior estimate of $0.25. Jefferies Group has a “Buy” rating and a $5.00 price objective on the stock.
TRADEMARK VIOLATION WARNING: “Xenon Pharmaceuticals Inc. to Post Q4 2017 Earnings of $0.22 Per Share, Jefferies Group Forecasts (XENE)” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/xenon-pharmaceuticals-inc-to-post-q4-2017-earnings-of-0-22-per-share-jefferies-group-forecasts-xene/1695428.html.
Separately, Zacks Investment Research upgraded shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, October 5th.
Xenon Pharmaceuticals (XENE) opened at $2.45 on Thursday. Xenon Pharmaceuticals has a 1-year low of $2.25 and a 1-year high of $9.95.
In other news, Director Michael R. Hayden acquired 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 14th. The stock was bought at an average cost of $2.75 per share, for a total transaction of $41,250.00. Following the acquisition, the director now directly owns 161,187 shares in the company, valued at $443,264.25. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Bvf Partners L. P/Il acquired 41,344 shares of the firm’s stock in a transaction that occurred on Monday, August 14th. The stock was purchased at an average price of $2.70 per share, with a total value of $111,628.80. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 162,739 shares of company stock valued at $431,125. 9.40% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. DAFNA Capital Management LLC raised its holdings in Xenon Pharmaceuticals by 11.2% in the 2nd quarter. DAFNA Capital Management LLC now owns 377,695 shares of the biopharmaceutical company’s stock worth $1,190,000 after acquiring an additional 38,081 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Xenon Pharmaceuticals by 90.1% in the 1st quarter. Renaissance Technologies LLC now owns 217,090 shares of the biopharmaceutical company’s stock worth $868,000 after acquiring an additional 102,890 shares during the last quarter. K2 Principal Fund L.P. raised its holdings in Xenon Pharmaceuticals by 40.6% in the 2nd quarter. K2 Principal Fund L.P. now owns 164,510 shares of the biopharmaceutical company’s stock worth $518,000 after acquiring an additional 47,535 shares during the last quarter. Scotia Capital Inc. raised its holdings in Xenon Pharmaceuticals by 36.0% in the 2nd quarter. Scotia Capital Inc. now owns 35,629 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 9,426 shares during the last quarter. Finally, KCG Holdings Inc. purchased a new position in Xenon Pharmaceuticals in the 1st quarter worth approximately $122,000. Institutional investors own 55.29% of the company’s stock.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).
Receive News & Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.